Controlled double-blind trail of flavoxate in painful conditions of the lower urinary tract.
A double-blind, placebo-controlled trial of the antispasmodic flavoxate (600 mg. daily) was carried out in 60 patients suffering from painful conditions of the lower urinary tract arising from inflammation and/or infection or from spasm following diagnostic or therapeutic procedures. Statistically significant improvement was noted in frequency and suprapubic pain, and marked relief was also afforded in dysuria, hesitancy and burning. Apart from dryness of the mouth, the incidence and type of side-effects reported were similar in both groups of patients and were probably not drug related. Fewer patients interrupted treatment with flavoxate because of inefficacy than in the placebo group, the difference being statistically significant.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D003556:Cystitis / Q000188:drug therapy; D003558:Cystoscopy / Q000009:adverse effects; D004106:Dilatation; D005260:Female; D005419:Flavonoids / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy; D010276:Parasympatholytics / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D010880:Piperidines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D010919:Placebos; D011472:Prostatitis / Q000188:drug therapy; D013035:Spasm / Q000209:etiology; D014526:Urethritis / Q000188:drug therapy; D014546:Urinary Catheterization / Q000009:adverse effects; D014551:Urinary Tract / Q000187:drug effects; D014552:Urinary Tract Infections / Q000150:complications; D014567:Urography / Q000009:adverse effects; D014570:Urologic Diseases / Q000188:drug therapy*
D005419:Flavonoids; D010276:Parasympatholytics; D010880:Piperidines; D010919:Placebos